Insider Buying: Cipher Pharmaceuticals (TSE:CPH) Director Purchases C$283,200.00 in Stock

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) Director Craig Mull purchased 20,000 shares of the business’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the completion of the acquisition, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. The trade was a 2.02% increase in their position.

Cipher Pharmaceuticals Stock Up 1.5%

TSE:CPH traded up C$0.21 during mid-day trading on Tuesday, hitting C$14.63. 5,804 shares of the company’s stock traded hands, compared to its average volume of 30,545. The company has a fifty day moving average of C$15.33 and a 200 day moving average of C$16.51. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.67 and a current ratio of 1.59. Cipher Pharmaceuticals Inc. has a twelve month low of C$12.48 and a twelve month high of C$20.56. The company has a market capitalization of C$371.82 million, a P/E ratio of 13.06 and a beta of 1.05.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported C$0.21 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. The firm had revenue of C$17.14 million during the quarter. On average, analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.